High dose brachytherapy as monotherapy for intermediate risk prostate cancer.

Purpose: We evaluated our retrospective, single institution experience with high dose rate brachytherapy as monotherapy for intermediate risk prostate cancer.

Materials And Methods: Our cohort included 284 patients with intermediate risk prostate cancer, defined as clinical stage T2b/T2c, Gleason score 7 and/or prostate specific antigen 10 to 20 ng/ml, and 1-year minimum followup. Treatment was 2 high dose rate brachytherapy sessions at 3 fractions of 6.

Adult urinary bladder rhabdomyosarcoma.

Rhabdomyosarcomas, malignant neoplasms exhibiting skeletal muscle differentiation, are the most common childhood sarcomas and most commonly arise in the head-and-neck region. Embryonal rhabdomyosarcomas of the genitourinary tract also occur in children, but are distinctly uncommon in adults. We report a case of embryonal rhabdomyosarcoma arising in the bladder of a 39-year-old woman who presented with urgency, frequency, and gross hematuria.